Key Developments: DexCom Inc (DXCM.O)
21.18USD
17 May 2013
$1.73 (+8.89%)
$19.45
$19.46
$21.19
$19.46
1,331,180
480,116
$21.19
$10.26
Latest Key Developments (Source: Significant Developments)
DexCom Inc Receives U.S. FDA Approves For Dexcom G4 PLATINUM Continuous Glucose Monitor
DexCom Inc announced that the U.S. Food and Drug Administration has approved its eagerly anticipated new continuous glucose monitoring system, the Dexcom G4 PLATINUM. Clinical trials report up to approximately 19% improvement in overall accuracy for the Dexcom G4 PLATINUM compared to the Seven Plus, and approximately a 30% improvement in accuracy in the hypoglycemia range (i.e., when blood glucose is less than 70mg/dl). The overall accuracy and ease of use for the Dexcom G4 PLATINUM sets a new standard for commercially available CGMs, making the Dexcom G4 PLATINUM the most-advanced CGM system available. The Dexcom G4 PLATINUM offers not only outstanding accuracy and performance, but many new capabilities, including: Longest transmission range, enabling improved patient flexibility and convenience A smaller, discrete profile that fits busy lifestyles A first-of-its-kind color LCD display for easy viewing Customizable alerts with specific tones "Hypo alert" setting at 55 mg/dl that provides an increased level of safety - a feature that no other device has. Full Article
DexCom Inc Receives CE Mark Approval For Dexcom G4 Continuous Glucose Monitoring System
DexCom Inc announced that it has received CE Mark (Conformité Européene) approval for fourth generation continuous glucose monitoring system, the Dexcom G4 system, enabling commercialization of the Dexcom G4 system in the European Union and the countries in Asia and Latin America that recognize the CE Mark. Full Article
DexCom Inc Announces Research Collaboration With JDRF
DexCom Inc announced that JDRF, has partnered with Dexcom, Inc. The goal of the partnership is to accelerate the development of a wireless smart transmitter that would allow a CGM system to communicate directly with an artificial pancreas control device currently being used for research studies, instead of only with a CGM receiver. JDRF will provide Dexcom up to $500,000 over 12 months in funding to complete the development, testing, and manufacturing of a custom smart transmitter prototype, which will be used for studies within JDRF's Artificial Pancreas Project academic research consortium. Full Article
DexCom Inc Announces Acquisition Of SweetSpot Diabetes Care, Inc.
DexCom, Inc. announced that it has entered into a definitive agreement to acquire SweetSpot Diabetes Care, Inc., a healthcare-focused information technology company, in an all stock transaction, with initial consideration of up to $4.5 million and performance based earnout consideration of up to an additional $4 million. The Company expects that the acquisition will close within the next several weeks. Full Article
DexCom Inc And Tandem Diabetes Care Announce CGM Development And Commercialization Agreement
DexCom Inc announced that it has entered into a Development and Commercialization Agreement with Tandem Diabetes Care, Inc. to integrate a future generation of DexCom’s continuous glucose monitoring (CGM) technology with Tandem’s t:slim Insulin Delivery System, the first ever touch-screen insulin pump. The Development and Commercialization Agreement is non-exclusive and limited to the U.S. market. Under the terms of the Agreement, Tandem will pay DexCom a technology license fee of $3 million, reimburse DexCom’s development, clinical and regulatory expenses, and upon commercialization of the combined system, Tandem will pay DexCom a royalty of $100 for each CGM-enabled insulin pump sold Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
